Daclatasvir 60 mg
Daclatasvir 60 mg Tablets are a direct-acting antiviral (DAA) targeting the hepatitis C virus replication process and are used in combination regimens for the treatment of chronic hepatitis C (HCV) infection, in accordance with internationally accepted treatment guidance.
Product Details
Therapeutic Class
Direct-Acting Antiviral (DAA)
NS5A Inhibitor
Indication
Treatment of chronic hepatitis C virus (HCV) infection in adults, as part of combination antiviral therapy, in accordance with WHO-recommended treatment guidelines.
Dosage & Administration
60 mg once daily, in combination with other antiviral agents, or as prescribed by a healthcare professional.
To be used strictly as part of a guideline-recommended HCV treatment regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO treatment guidelines.
*This combination is under patent protection in several markets. Supply, manufacture, or distribution is subject to applicable patent laws and local regulatory approvals.
Pack Size
28 tablets
Daclatasvir 60 mg
Daclatasvir 60 mg Tablets are a direct-acting antiviral (DAA) targeting the hepatitis C virus replication process and are used in combination regimens for the treatment of chronic hepatitis C (HCV) infection, in accordance with internationally accepted treatment guidance.
Product Details
Therapeutic Class
Direct-Acting Antiviral (DAA)
NS5A Inhibitor
Indication
Treatment of chronic hepatitis C virus (HCV) infection in adults, as part of combination antiviral therapy, in accordance with WHO-recommended treatment guidelines.
Dosage & Administration
60 mg once daily, in combination with other antiviral agents, or as prescribed by a healthcare professional.
To be used strictly as part of a guideline-recommended HCV treatment regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO treatment guidelines.
*This combination is under patent protection in several markets. Supply, manufacture, or distribution is subject to applicable patent laws and local regulatory approvals.
Pack Size
28 tablets
Daclatasvir 60 mg
Daclatasvir 60 mg Tablets are a direct-acting antiviral (DAA) targeting the hepatitis C virus replication process and are used in combination regimens for the treatment of chronic hepatitis C (HCV) infection, in accordance with internationally accepted treatment guidance.
Product Details
Therapeutic Class
Direct-Acting Antiviral (DAA)
NS5A Inhibitor
Indication
Treatment of chronic hepatitis C virus (HCV) infection in adults, as part of combination antiviral therapy, in accordance with WHO-recommended treatment guidelines.
Dosage & Administration
60 mg once daily, in combination with other antiviral agents, or as prescribed by a healthcare professional.
To be used strictly as part of a guideline-recommended HCV treatment regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO treatment guidelines.
*This combination is under patent protection in several markets. Supply, manufacture, or distribution is subject to applicable patent laws and local regulatory approvals.
Pack Size
28 tablets